Clinical experience with Liraglutide in 196 patients with type 2 diabetes from a tertiary care center in India.
BACKGROUND
GLP-1 receptor agonists (GLP-1 RA) are unique antidiabetic agents that have the ability to lower blood glucose without causing hypoglycemia, while at the same time promoting weight loss. Information on the efficacy and safety of GLP-1 RA in the Indian diabetic population is limited.


OBJECTIVE
(1) To evaluate the effect of GLP-1 RA, Liraglutide on glycemic control, and weight in obese Indian patients with type 2 diabetes. (2) To study the adverse event profile of Liraglutide in these patients in real-world clinical setting.


METHODS
Observational study conducted in a tertiary care hospital.


METHODS
Liraglutide was prescribed to 196 obese patients with type 2 diabetes who had poor glycemic control on oral medications ± insulin. The initial dose of Liraglutide was 0.6 mg, which was up-titrated to 1.2 mg after 1 week; further up-titration to 1.8 mg was done based on tolerance. Dipeptidyl peptidase-IV (DPP-IV) inhibitors were discontinued and dose of other medications adjusted according to clinical judgment during the study period.


RESULTS
Mean age of patients was 49.9 ± 9.6 years. Three month data were available for 175 patients out of a total of 196. At 3 months, glycosylated hemoglobin (HbA1c) was 7.6 ± 0.9% vs. 9.2 ± 1.9% at baseline (P = 0.007) and mean body weight was 96.0 ± 16.5 kg vs. 100.1 ± 17.5 kg at baseline (P < 0.001). Most common adverse events were nausea, burping, and eructation (10%).


CONCLUSIONS
Liraglutide significantly improves glycemic control with low risk of hypoglycemia and is associated with significant weight loss in obese Indian patients with type 2 diabetes mellitus.
Department of Endocrinology, Medanta the Medicity, Gurgaon, Haryana, India.
Parjeet
P
Kaur
Department of Endocrinology, Medanta the Medicity, Gurgaon, Haryana, India.
Sunil Kumar
SK
Mishra
Department of Endocrinology, Medanta the Medicity, Gurgaon, Haryana, India.
Ambrish
A
Mithal
Department of Endocrinology, Medanta the Medicity, Gurgaon, Haryana, India.
Meenal
M
Saxena
Department of Endocrinology, Medanta the Medicity, Gurgaon, Haryana, India.
Anshu
A
Makkar
Department of Clinical Research, Medanta the Medicity, Gurgaon, Haryana, India.
Pooja
P
Sharma
GLP-1 receptor agonists; India; obesity; type 2 diabetes